WuXi Biologics becomes first Chinese EU approved CDMO

By Ben Hargreaves

- Last updated on GMT

(Image: Getty/ Eivaisla)
(Image: Getty/ Eivaisla)

Related tags: Wuxi biologics, Wuxi, China, Hiv infection, Hiv, Manufacturing, facility

WuXi Biologics receives EMA GMP certification for the production of Trogarzo at its manufacturing facilities in Wuxi city and Shanghai, China.

A month ago​, WuXi Biologics told us that it expected to receive approval from the European Medicines Agency (EMA) for the facilities by May 2019. Yesterday, the EMA provided its current good manufacturing practice (cGMP) certification ahead of this projection.

The certification concerns drug substances and drug product manufacturing facilities in Wuxi city, and cell banking facilities in Shanghai.

Both sites are used in the production of Trogarzo (ibalizumab), which is a product developed by TaiMed Biologics and marketed in the US and Europe by Theratechnologies, indicated for the treatment of HIV-1 in heavily treated adults with multidrug resistance.

“This [certification] marks yet another great milestone that WuXi Biologics has achieved and lays a solid foundation for us to significantly expand our manufacturing capacity and capabilities,”​ said Chris Chen, CEO of WuXi Biologics.

In order to receive EMA approval for its facilities, WuXi Biologics told us that it had submitted written responses to the agency’s request for improvement to procedures.

Related news

Show more

Follow us

Products

View more

Webinars